Shares of Amgen Inc. AMGN inched 0.24% higher to $264.00 Monday, on what proved to be an all-around favorable trading session ...

Amgen's leukemia drug Blincyto infringes patents owned by Germany's Lindis Biotech, a Delaware federal jury said in a verdict ...

Shares of Amgen Inc. AMGN slumped 0.21% to $265.95 Tuesday, on what proved to be an all-around dismal trading session for the ...

We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

The latest trading day saw Amgen (AMGN) settling at $264, representing a +0.24% change from its previous close.

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Additionally, AbbVie is an exceptional income stock. It's a Dividend King, with 52 consecutive years of payout increases ...

Amgen stock gained more than 2% in Friday’s morning session after foreign weightloss drug competitor Novo Nordisk (NVO) ...

Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $263.38 which represents a slight increase of $2.19 or 0.84% from the prior close of $261.19. The stock opened at $269 and touched a low ...

StockNews.com lowered shares of Amgen (NASDAQ:AMGN – Free Report) from a strong-buy rating to a buy rating in a research ...

Novo Nordisk's CagriSema shows 22.7% weight loss in Phase 3 trials, while tolerability concerns grow. MariTide offers ...